A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France

2017 ◽  
Vol 25 (7) ◽  
pp. 2055-2062 ◽  
Author(s):  
Florence Joly ◽  
Jean-Christophe Eymard ◽  
Laurence Albiges ◽  
Thierry Nguyen ◽  
Aline Guillot ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Vascular Endothelial ◽  
First Line ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

scholarly journals Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Bo Zhao ◽  
Laura S. Wood ◽  
Karen James ◽  
Brian I. Rini
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cardiac Ischemia ◽  
Vascular Endothelial ◽  
Cardiac Events ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.

Sign in / Sign up

Export Citation Format

Share Document